Table 2.
Clinic Visits and Antibiotic Treatment by SCCmec Type and PVL Status
| Characteristic | SCCmec II (N = 199) | SCCmec IV (N = 88) | P Value | SCCmec IV PVL(+) (N = 50) | SCCmec IV PVL(−) (N = 38) | P Value | |
|---|---|---|---|---|---|---|---|
| Clinic visits/participant | Mean (SD) | 13.3 (7.6) | 11.8 (7.6) | .15 | 9.9 (4.5) | 14.3 (9.9) | .014 |
| Clinic visits/year follow-up | Mean (SD) | 6.1 (3.0) | 5.8 (2.6) | .40 | 5.3 (2.0) | 6.4 (3.1) | .05 |
| Visits with inhaled, oral, or IV antibiotics prescribed | n (%) | 1642 (60.6%) | 549 (51.8%) | <.001 | 271 (50.1%) | 278 (53.4%) | .28 |
| Prescriptions of TMP-SMX* | % | 33.0 | 35.0 | .37 | 31.0 | 39.2 | .049 |
| Prescriptions of fluoroquinolone* | % | 23.4 | 25.9 | .25 | 22.9 | 28.8 | .12 |
| Prescriptions of linezolid* | % | 23.2 | 18.2 | .01 | 20.7 | 15.8 | .15 |
| Prescriptions of tetracycline* | % | 8.6 | 7.3 | .37 | 11.4 | 3.2 | <.001 |
| Prescriptions of rifampin* | % | 4.7 | 3.8 | .47 | 5.6 | 2.2 | .046 |
| Prescriptions of clindamycin* | % | 0.2 | 1.6 | <.001 | 0.7 | 2.5 | .18 |
| Prescriptions of non-MRSA active oral antibiotic*,† | % | 6.9 | 8.0 | .39 | 7.8 | 8.3 | .88 |
Abbreviations: IV, intravenous; MRSA, methicillin-resistant Staphylococcus aureus; PVL, Panton-Valentine-leukocidin; SCCmec, staphylococcal cassette chromosome mec; SD, standard deviation; TMP-SMX, trimethoprim-sulfamethoxazole. Bold text indicates P Value <0.05.
*Expressed as a percentage of oral antibiotics prescribed.
†These were antibiotics classically not considered active for MRSA (eg, amoxicillin).